Skip to main content
Top
Published in: Applied Health Economics and Health Policy 4/2013

01-08-2013 | Current Opinion

New Anti-Rebate Legislation in South Korea

Authors: Su-Yeon Yu, Bong-Min Yang, Jin-Hyun Kim

Published in: Applied Health Economics and Health Policy | Issue 4/2013

Login to get access

Abstract

The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to have the ability to bring criminal charges against doctors and pharmacists for receiving illegal kickbacks from drug companies. Previously, provision of illegal kickbacks by drug companies led to criminal punishment of the drug companies alone, leaving doctors and pharmacists unpunished as the recipients. With the introduction of the “Dual Punishment System (DPS)” reform, criminal punishment for illegal rebates is extended to those receiving illegal kickbacks. Although bitter controversy erupted among stakeholders when the reform was first drafted, a civic group participated in the reform process and effectively influenced the legislative process to a successful end. Some interim outcomes from the DPS in terms of bringing illegal practices to account have already been reported since the policy’s implementation in November 2010. The reform background, goals, potential issues, and policy implications are explored in this study with the objective of providing further insight into drug policy for other countries that face similar challenges in the area of drug marketing.
Footnotes
1
Drug-related rebates come in various forms. Some rebates are legally authorized while others are against the law. For example, in a risk-sharing scheme within a drug reimbursement system, rebates in the form of payback to payers are legally approved and are often even required. However, rebates in the form of covering expenses of academic conference participation, providing material gifts or discounts, and supporting various events organized by prescribers, dispensers, and medical institutions, are considered unethical and illegal by the Pharmaceutical Affairs Acts. The rebates that are the subject of this study are the illegal ones.
 
Literature
1.
go back to reference Korea Fair Trade Commission. Corrective Measures against improper concerted acts by 10 pharmaceutical companies. [online]. . Accessed 1 March 2013. Korea Fair Trade Commission. Corrective Measures against improper concerted acts by 10 pharmaceutical companies. [online]. https://static-content.springer.com/image/art%3A10.1007%2Fs40258-013-0029-x/MediaObjects/40258_2013_29_Figa_HTML.gif . Accessed 1 March 2013.
2.
go back to reference US International Trade Commission. US-Korea Free Trade Agreement: Potential Economy-wide and Selected Sectoral Effects, Chapter 3. Sector-specific assessment, 2007. p. 65–6. US International Trade Commission. US-Korea Free Trade Agreement: Potential Economy-wide and Selected Sectoral Effects, Chapter 3. Sector-specific assessment, 2007. p. 65–6.
3.
go back to reference The Ministry of Health and Welfare in Korea. Reducing price of a drug involved in rebates, [online]. . Accessed 12 July 2012. The Ministry of Health and Welfare in Korea. Reducing price of a drug involved in rebates, [online]. https://static-content.springer.com/image/art%3A10.1007%2Fs40258-013-0029-x/MediaObjects/40258_2013_29_Figb_HTML.gif . Accessed 12 July 2012.
7.
go back to reference National Health Insurance Corporation. Statistical Yearbook. 2010. National Health Insurance Corporation. Statistical Yearbook. 2010.
8.
go back to reference Yang B, Bae E, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea’s National Health Insurance. Health Aff. 2008;27(1):179–87.CrossRef Yang B, Bae E, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea’s National Health Insurance. Health Aff. 2008;27(1):179–87.CrossRef
9.
go back to reference Lee H, Kim J. Delisting policy reform in South Korea: failed or policy change? Value Health. 2011;15:204–12.PubMedCrossRef Lee H, Kim J. Delisting policy reform in South Korea: failed or policy change? Value Health. 2011;15:204–12.PubMedCrossRef
11.
go back to reference Lim D, Choi H, Joung M, et al. The Study on Pharmaceutical Industry Anaylsis, Korea Health Industry Development Institute. 2010. Lim D, Choi H, Joung M, et al. The Study on Pharmaceutical Industry Anaylsis, Korea Health Industry Development Institute. 2010.
12.
go back to reference Korea Pharmaceutical Statistics. Korea Pharmaceutical Manufacturers Association. 2010. Korea Pharmaceutical Statistics. Korea Pharmaceutical Manufacturers Association. 2010.
13.
go back to reference Lee G, Seo K, Lim D, et al. Fact and analysis of the research and development in health industry. Korea Health Industry Development Institute. 2009. Lee G, Seo K, Lim D, et al. Fact and analysis of the research and development in health industry. Korea Health Industry Development Institute. 2009.
14.
go back to reference Joung M, Lee B, Joung Y, et al. The study on pharmaceutical industry. Korea Health Industry Development Institute. 2008. Joung M, Lee B, Joung Y, et al. The study on pharmaceutical industry. Korea Health Industry Development Institute. 2008.
15.
go back to reference The Ministry of Health and Welfare in Korea. New Policy of Drug Price. [online]. Accessed 1 March 2013. The Ministry of Health and Welfare in Korea. New Policy of Drug Price. [online]. https://static-content.springer.com/image/art%3A10.1007%2Fs40258-013-0029-x/MediaObjects/40258_2013_29_Figc_HTML.gif Accessed 1 March 2013.
16.
go back to reference Taylor D, Mrazek M, Mossialos E. Regulating pharmaceuticals distribution and retail pharmacy in Europe. In: Mossialos E, Mrazek M, Walley T, editors. Regulating pharmaceuticals in Europe. Maidenhead: Open University Press; 2004. p. 196–212. Taylor D, Mrazek M, Mossialos E. Regulating pharmaceuticals distribution and retail pharmacy in Europe. In: Mossialos E, Mrazek M, Walley T, editors. Regulating pharmaceuticals in Europe. Maidenhead: Open University Press; 2004. p. 196–212.
17.
go back to reference Joung Y, Lee B, Joung M, et al. A study on the development of pharmaceutical wholesalers industry. Korea Health Industry Development Institute. 2010. Joung Y, Lee B, Joung M, et al. A study on the development of pharmaceutical wholesalers industry. Korea Health Industry Development Institute. 2010.
20.
go back to reference Korean Food and Drug Administration. The Pharmaceutical Affairs Acts. 2010. Korean Food and Drug Administration. The Pharmaceutical Affairs Acts. 2010.
22.
go back to reference The Board of Audit and Inspection of Korea. Audit on Management of NHI drugs. 2012. The Board of Audit and Inspection of Korea. Audit on Management of NHI drugs. 2012.
25.
go back to reference Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–9.PubMed Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–9.PubMed
26.
go back to reference Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527–38.PubMedCrossRef Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527–38.PubMedCrossRef
27.
go back to reference McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73–85.PubMed McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73–85.PubMed
29.
go back to reference Godman B, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.PubMed Godman B, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.PubMed
30.
go back to reference Brkicic LS, Godman B, Voncina L, et al. Initiatives to improve prescribing efficiency for drugs to treat Parkinson’s disease in Croatia: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):373–84.PubMed Brkicic LS, Godman B, Voncina L, et al. Initiatives to improve prescribing efficiency for drugs to treat Parkinson’s disease in Croatia: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):373–84.PubMed
Metadata
Title
New Anti-Rebate Legislation in South Korea
Authors
Su-Yeon Yu
Bong-Min Yang
Jin-Hyun Kim
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 4/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0029-x

Other articles of this Issue 4/2013

Applied Health Economics and Health Policy 4/2013 Go to the issue